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Abstract
Background: In patients with a venous outflow obstruction following iliofemoral deep 
vein thrombosis stenting of the venous tract to prevent or alleviate postthrombotic syn-
drome is applied with increasing frequency. The impact of the quality of anticoagulant 
therapy with vitamin K antagonists (VKAs) on the development of in-stent thrombosis 
is currently unknown.
Objectives: To determine the association between the quality of postinterventional 
VKA treatment and the occurrence of in-stent thrombosis.
Methods: Seventy-nine patients with iliofemoral and/or caval venous stent place-
ment for obstruction of the venous outflow were included in this study. All patients 
received postinterventional VKA. The quality of VKA anticoagulant therapy was ex-
pressed as the time within therapeutic range (TTR) calculated using the linear in-
terpolation method and as the proportion of International Normalized Ratio (INR) 
values < 2.0. In-stent thrombosis was assessed by the use of duplex ultrasound. 
Survival analysis (Kaplan-Meier curves, Cox regression) was used to analyze the data.
Results: In-stent thrombosis developed in 16 patients (20.3%). The total population 
had a mean TTR of 64.0% (±19.0) and a mean proportion of INR values < 2.0 of 
11.6% (±12.0). Overall, a TTR < 49.9% was associated with an increased risk of in-
stent thrombosis. The multivariable adjusted analysis showed a hazard ratio (HR) of 
0.96 (95% confidence interval [CI], 0.92-0.99; P = .02) per 1% increase in TTR. The 
proportion of INR values < 2.0 had no significant association with the occurrence of 
in-stent thrombosis: HR 0.98 (95% CI, 0.91-1.06; P = .66).
Conclusions: We conclude that the quality of anticoagulant treatment reflected in the 
TTR following a venous stenting procedure is an important independent determinant 
for the risk of in-stent thrombosis. The role of anticoagulant treatment for the pre-
vention of in-stent thrombosis following stenting procedures therefore merits further 
research.
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Essentials
• Uniform evidence-based guidelines on anticoagulant management after venous stenting are lacking.
• This study assessed quality of vitamin K antagonist (VKA) therapy and its role in in-stent thrombosis.
• We found a decreased risk of in-stent thrombosis with increasing time within therapeutic range.
• Quality of VKA therapy after stenting is an important determinant for risk of in-stent thrombosis.
1  | INTRODUCTION
Percutaneous transluminal angioplasty (PTA) and venous stenting 
of the caval and iliofemoral veins have become more common and 
are considered to be effective and safe treatment modalities for 
eliminating (central) venous outflow obstructions and the restora-
tion of venous flow. Literature suggests good mid- to long-term 
patency rates as well as objective and subjective clinical improve-
ment.1-5 However, in-stent thrombosis is the most important com-
plication that can diminish effectiveness or reverse treatment 
outcomes.
Venous stenting is thought to restore the venous outflow, 
to reduce postthrombotic morbidity in case of residual venous 
flow obstructions following acute iliofemoral deep vein throm-
bosis (DVT), and/or to relieve symptoms if postthrombotic syn-
drome (PTS) or chronic deep venous pathology have already 
developed. Despite adequate conservative treatment involv-
ing early anticoagulation, early compression therapy, and early 
mobilization, PTS will develop in 25%-50% of patients with an 
acute iliofemoral DVT.6-8 Venous stenting can be performed in 
the acute phase as an adjunct to catheter-directed thromboly-
sis (CDT), when there is underlying venous pathology (ie, iliac 
vein compression syndromes), or in the chronic phase to allevi-
ate complaints when residual venous obstruction due to post-
thrombotic changes are present.9-13 Venous stenting is most 
frequently considered for chronic deep venous obstructions, 
either due to compression syndromes, acquired causes (eg, 
postthrombotic synechiae), or congenital causes (eg, anatomic 
anomalies).
Thus far, there is no consensus regarding the postprocedural 
anticoagulant management.14,15 Current international guidelines do 
not provide specific recommendations on anticoagulation therapy 
after venous stenting mainly due to lack of evidence.16 A large vari-
ety in anticoagulant management following venous stent placement 
either for chronic venous obstruction or directly after CDT in the 
acute thrombotic phase has been reported.14 Despite the rapidly in-
creased use of direct oral anticoagulants (DOACs), treatment with 
vitamin K antagonists (VKAs) still appears to be preferred by clinical 
experts.14,15 The duration of anticoagulant therapy varies from 3 to 
12 months, usually with a target International Normalized Ratio (INR) 
range of 2.0-3.0.15 While time within therapeutic range (TTR) of VKA 
therapy in acute DVT is known to have substantial impact on recur-
rent DVT,17,18 the role of TTR during VKA therapy for the preven-
tion of in-stent thrombosis after venous stenting remains unknown. 
In addition, INR values < 2.0 are an established risk factor for both 
recurrent venous thromboembolism17 and PTS.19,20 Taking this into 
consideration, we hypothesized that the quality of anticoagulation 
most likely also influences the effectiveness of venous stenting in 
relation to stent patency.
Therefore, we evaluated the association of the quality of postin-
terventional VKA anticoagulation with the occurrence of in-stent 
thrombosis following caval and/or iliofemoral venous stenting, both 
in the acute postthrombotic phase and in the setting of chronic deep 
venous obstruction.
2  | METHODS
2.1 | Study design and patient selection
Patients were recruited from a cohort study that was followed 
at the Maastricht University Medical Centre, the Netherlands, 
between March 2009 and January 2013. Data on the interven-
tions were collected prospectively and were entered in a cohort 
database. In all patients, the indication for venous stent place-
ment, being either the prevention or treatment of PTS with the 
presence of an acute or chronic obstruction of the caval and/
or iliofemoral vein segments, was objectified. Patients were 
eligible only if VKA was used for at least 3 months follow-
ing the performed intervention and follow-up data of at least 
1 year were available. In total, 108 patients from this cohort, 
who were treated at the Department of Vascular Surgery with 
venous stent placement for either acute cavo-iliofemoral DVT 
or chronic deep venous obstructions, met inclusion criteria and 
were invited to participate in the current study. Ultimately, 79 
patients (73.1%) consented and were included in this study. All 
patients were required to provide informed consent to retrieve 
data regarding their INR measurements from their anticoagu-
lation clinic records. Institutional review board approval was 
 obtained (METC 14-4-081).
K E Y W O R D S
anticoagulants, deep vein thrombosis, International Normalized Ratio, postthrombotic 
syndrome, stents
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2.2 | Treatment
2.2.1 | Preinterventional workup
A standardized preinterventional workup was performed in all pa-
tients in the cohort and consisted of clinical evaluation, extensive 
duplex ultrasound assessment, and magnetic resonance venography. 
Clinical assessment was used to determine the presence and sever-
ity of signs, symptoms, and complaints. Duplex ultrasound assessed 
the inferior caval vein as well as the separate vein segments of the 
affected leg (ie, common iliac vein, external iliac vein, common femo-
ral vein, femoral vein, deep femoral vein, and popliteal vein) for un-
derlying pathology, signs of flow impairment, recanalization, luminal 
narrowing, vein wall thickening, and external compression. Magnetic 
resonance venography was used to visualize the extent and sever-
ity of intraluminal postthrombotic changes, external compression, 
and collateralization, as well as the exact location of the trabeculae 
within the venous lumen.21
The localization of the initial obstruction indicative for venous 
stenting was described using the lower-extremity thrombosis (LET) 
score, which categorized patients into 1 of 4 categories (I = calf veins, 
II = femoropopliteal, III = femoroiliac, IV = inferior caval vein) based 
on the results from the preinterventional workup imaging studies.22
2.2.2 | Venous stenting
Indications for venous stent placement were classified as either 
acute cavo-iliofemoral thrombosis, or chronic deep venous ob-
struction due to the presence of postthrombotic sequelae (ie, PTS 
with postthrombotic synechiae), or (nonthrombotic) iliac vein com-
pression syndromes. Patients were treated with PTA and stenting. 
Stenting in the acute thrombotic phase was usually performed fol-
lowing treatment with ultrasound-accelerated CDT.
All procedures were performed in a dedicated angio suite under 
sedation. In patients using VKA at the time of intervention, the pro-
cedure was performed under full anticoagulation (ie, VKAs were 
continued in the days preceding the intervention in the case of an 
INR < 4.0). If patients did not have anticoagulant therapy, 5.000 
International Units (IU) of unfractionated heparin was administered 
at the start of the procedure. Another 5.000 IU was given at the 
discretion of the treating physician in case of a prolonged duration 
of the intervention. In case ultrasound-accelerated CDT was per-
formed prior to the stenting procedure, patients were treated with 
therapeutic doses of low-molecular-weight heparin (LMWH) during 
thrombolysis and VKA treatment was temporarily interrupted.
Venous access was obtained via the ipsilateral popliteal vein 
under ultrasound guidance, preferably at least 15 cm distal to the 
deep femoral confluence. Venous thrombolysis was performed 
using Urokinase (Medacinase, Lamepro) and the Ekos Endowave 
system (EKOS Corporation). Recanalization, PTA, and venous stent-
ing were performed according to international and local guide-
lines.5,23 Following recanalization, PTA and subsequent stenting 
of the affected vein segments was performed. The proximal and 
distal landing zones of the stents were placed in seemingly healthy 
vein segments, meaning the absence of trabeculations. A hybrid 
procedure including endophlebectomy was performed in case the 
intraluminal synechiae obstructed the femoral junction. If a low in-
flow of the recanalized vein segment was anticipated or observed 
during preoperative venography, an arteriovenous fistula using a 
loop-shaped external supported polytetrafluoroethylene graft was 
created.
Self-expandable stents with diameter sizes ranging from 12 to 
16 mm in the iliofemoral tract to 24 mm in the caval tract were used 
in all cases: Sinus-XL, Sinus-XL Flex, Sinus-Venous (Optimed), Zilver 
Vena (Cook). To reconstruct the confluence of the vena cava in the 
limited number of patients with bilaterally affected iliac tracts, bal-
loon expandable stents such as the AndraStent (Andramed) were 
used.23
2.2.3 | Postinterventional anticoagulation therapy
In patients using VKA prior to the intervention, anticoagulant therapy 
was continued for at least another 6 months. All other patients were 
started on LMWH directly after the procedure and were started on a 
VKA according to international guidelines concomitantly at the first 
postinterventional day, after which VKA was continued for at least 
6 months.24 VKA therapy was targeted at an INR range of either 2.0-
3.5 or 2.5-4.0. The preferred target INR and treatment duration was 
at the discretion of the treating physician.
2.3 | Clinical follow-up
Following the intervention, standard clinical follow-up was per-
formed at the outpatient clinic after 2 and 6 weeks, as well as after 3, 
6, and 12 months and annually thereafter. Recurrence of symptoms 
could necessitate earlier consultations and assessments.
At every follow-up visit, a standardized clinical evaluation was 
performed by the treating physician recording signs, symptoms, 
and complaints, as well as the use of anticoagulants, experienced 
bleedings, in-stent thrombosis, or recurrent venous thromboembo-
lism. Duplex ultrasound was performed to assess the patency of the 
(stented) venous tract. Treatment decisions regarding anticoagula-
tion, compression therapy, and reinterventions were based on these 
assessments.
The severity of complaints was measured using the Clinical-
Etiological-Anatomical-Pathophysiological (CEAP) classification25 
and Venous Clinical Severity Score (VCSS)26. The VCSS differenti-
ates venous disease severity into absent (0-3), mild to moderate (4-
7), or severe (≥8).27
Patient records were retrieved from the patient's individual an-
ticoagulation clinic to ascertain start and stop dates of VKA treat-
ment, other indications for VKA therapy, target INR, type of VKA 
used (acenocoumarol or phenprocoumon), measured INR values, and 
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whether adjunctive treatment with LMWH was instructed in case of 
INR values < 2.5 beyond the initial treatment period.
2.4 | Definition of outcomes
Primary outcome was the incidence of in-stent thrombosis, which 
was defined as an objectified (recurrent) thrombotic event leading to 
a full obstruction in the stented trajectory.
Quality of anticoagulant treatment was described by the TTR as 
well as proportion of INR values < 2.0 for the overall treatment time. 
The linear interpolation method as proposed by Rosendaal et al28 
was used to calculate the TTR. This method assumes a linear rela-
tionship in time between 2 INR measurements.
Bleeding complications were registered and categorized fol-
lowing the definition as stated by the ISTH.29 Major bleedings in-
cluded (a) fatal bleedings, (b) symptomatic bleedings in critical areas 
or organs (intracranial, intraspinal, intraocular, retroperitoneal, in-
tra-articular, pericardial, or intramuscular), or (c) causing a fall in he-
moglobin of ≥2 g/dL (≈1.24 mmol/L) or the need for a transfusion of 
≥2 units of packed red blood cells or whole blood.
2.5 | Statistical analysis
Descriptive statistics were used to compare baseline characteristics. 
Continuous variables are reported as means ± standard deviations 
(SD) or medians with their interquartile ranges (IQRs) as appropri-
ate. Categorical data are presented by their absolute numbers and 
corresponding percentages. Baseline data are presented based on 
prescribed target INR, either “low” (target INR, 2.0-3.5) or “high” 
(target INR, 2.5-4.0). The outcome data were presented according to 
the different treatment indications: acute cavo-iliofemoral DVT and 
chronic deep venous obstruction due to postthrombotic sequelae, 
or nonthrombotic pathology (eg, compression syndromes). To com-
pare groups, parametric and nonparametric tests were performed 
as appropriate.
Receiver operating characteristic (ROC) curves were used to 
determine the cutoff points for the outcome in stent thrombosis 
in relation to TTR and the proportion of INR values < 2.0, respec-
tively. Based on expected differences seen in the literature,18,30 
cutoff points were determined for the entire population as well as 
restricted to the population with acute DVT and the population with 
chronic deep venous obstruction due to postthrombotic sequelae, 
respectively. The cumulative risk of in-stent thrombosis based on 
the determined cutoff values for the entire population is presented 
using Kaplan-Meier curves. Patients were censored when follow-up 
ended due to terminated VKA therapy or at the last performed pa-
tency measurement. To compare groups, log-rank tests were per-
formed. Person time was calculated from the date of intervention 
up to the date that in-stent thrombosis occurred, VKA therapy was 
terminated or the last reported patency measurement was per-
formed. TTRs were compared between patients with and without 
in-stent thrombosis for the entire population, as well as restricted to 
DVT patients with acute DVT and chronic deep venous obstruction 
separately.
Cox regression was used to express the association between 
the independent variables TTR and percentage of INR measure-
ments < 2.0 separately. Analyses were performed restricted to 
patients treated for chronic deep venous obstruction as a result of 
postthrombotic sequelae and adjusted for possible confounders in 
relation to the development of in-stent thrombosis.
The risk for in-stent thrombosis is presented using hazard ra-
tios with their accompanying 95% confidence intervals (95% CIs). 
Selection of variables to be included in the multivariable-adjusted 
models was based either on the association between exposure and 
the development of in-stent thrombosis as described in the litera-
ture or on the observed association in our data (P < 0.20). Ultimately, 
the multivariate model included the variables age at inclusion, sex, 
VKA type used (acenocoumarol or phenprocoumon), and adjunctive 
LMWH use if INR value was <2.5 beyond the initial treatment period. 
The proportional hazards assumption was tested for all variables.
A significance level of 0.05 (two-sided) or less was considered 
significant. As <5% of missing data were encountered, no imputation 
was performed. All analyses were performed using SPSS, version 25 
(IBM Corporation).
3  | RESULTS
Seventy-nine of the 108 eligible patients (73.1%) provided informed 
consent to retrieve additional data from their individual anticoagu-
lation clinic and could therefore be included in this study. Forty 
(50.6%) patients had a “low” target INR (INR range, 2.0-3.5) and 
39 (49.4%) patients had a “high” target INR (INR range, 2.5-4.0). 
Baseline characteristics are presented in Table 1. Overall, patients 
were predominantly female (n = 52, 65.8%) and had a mean age of 
41.3 ± 15.5 years. Most thrombi were located in the left lower ex-
tremity (n = 47, 59.5%) and were classified as LET-III (n = 53, 67.1%).22 
Disease severity differed between groups with patients on a “high” 
target INR more frequently known with a previous, healed venous 
ulcer (CEAP-C525 7 [17.9%] vs 1 [2.5%] respectively; P = .02) and 
reporting a higher severity of venous complaints according to the 
VCSS26 (8.92 ± 3.52 vs 6.27 ± 2.66 respectively, P = .03).
Neither primary nor secondary outcomes differed between 
patient groups based on treatment indication (Table 2). In-stent 
thrombosis developed in 16 patients (20.3%) after a median of 67.0 
(6.0-264.5) days within a median follow-up of 1200 (1037-1363) 
days. Four patients (25.0%) were stented during the acute post-
thrombotic phase and 12 (75.0%) patients for chronic postthrom-
botic deep venous obstruction (P = .27). No in-stent thromboses 
occurred in patients stented for a nonthrombotic indication.
All primary interventions included PTA as well as stent place-
ment. An adjunctive endophlebectomy, creation of an arteriove-
nous fistula, or a combination of both was performed in 3 (3.8%), 2 
(2.5%), and 14 (17.7%) patients, respectively. Venous stenting was 
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most frequently performed in the left venous tract (n = 61, 77.2%), 
either isolated (n = 36, 45.6%) or combined with stent placement in 
the right and/or caval venous tract (n = 14, 17.7% and n = 11, 13.9%, 
respectively).
Acenocoumarol was the most commonly prescribed anticoagu-
lant during the postinterventional VKA therapy: 57.0% versus 41.8% 
using phenprocoumon. The median duration of VKA treatment was 
351 (136-769) days. During treatment, there were no differences in 
mean INR, TTR, or proportion of INR < 2.0 between patients stented 
for acute DVT or chronic deep venous obstruction with chronic post-
thrombotic sequelae, or nonthrombotic causes: mean INRs were 3.08 
(±0.63), 3.15 (±0.46), and 3.12 (±0.38), P = .30; mean TTR, 66.8% 
(±13.6), 63.2% (±19.5), and 67.7% (±24.9), P = .80; and the proportion 
of INRs < 2.0 were 17.3% (±17.9), 10.7% (±10.5), and 12.2% (±15.4), 
P = .35, respectively. Supplementary use of LMWH if INR dropped 
below 2.5 beyond the initial treatment period was prescribed in 5 
(50.0%), 22 (34.4%), and 1 (20.0%) patients, respectively (P = .48).
TA B L E  1   Baseline Characteristics
 
Low INR 
range, n = 40
High INR 
range, n = 39 Total, n = 79
Age, y, mean 42.9 (± 16.1) 39.7 (± 12.8) 41.2 (± 14.5)
Sex, male 11 (27.5) 16 (41.0) 27 (34.2)
Indication for venous stenting
Acute DVT 6 (15.0) 4 (10.3) 10 (12.7)
Chronic 
postthrombotic 
sequelae
30 (75.0) 34 (87.2) 64 (81.0)
Nonthrombotic causes 
(eg, compression 
syndromes)
4 (10.0) 1 (2.6) 5 (6.3)
Affected side
Left 25 (62.5) 22 (56.4) 47 (59.5)
Right 5 (12.5) 8 (20.5) 13 (16.5)
Bilateral 7 (17.5) 7 (17.9) 14 (17.7)
Unknown 3 (7.5) 2 (5.1) 5 (6.3)
LET classificationa 
IV 6 (15.0) 7 (17.9) 13 (16.5)
III 26 (65.0) 25 (64.1) 51 (64.6)
Unknown 4 (10.0) 6 (15.4) 10 (12.7)
Not applicable 4 (10.0) 1 (2.6) 5 (6.3)
VCSS, meanbc  6.27 (±2.66) 8.92 (± 3.52) 7.50 (± 3.32)
CEAP classification. Clinical scored 
C6: Active venous 
ulcer
2 (5.0) 3 (7.7) 5 (6.3)
C5: Healed venous 
ulcerc 
1 (2.5) 7 (17.9) 8 (10.1)
C4: 
Lipodermatosclerosis 
or atrophie blanche
8 (20.0) 10 (25.6) 18 (22.8)
C0-C3e  24 (60.0) 17 (43.6) 41 (51.9)
Unknown 5 (12.5) 2 (5.1) 7 (8.9)
Previous DVTf  35 (87.5) 35 (89.7) 70 (88.6)
Ipsilateral 31 (88.6) 34 (97.1) 65 (92.9)
Contralateral 1 (2.9) 1 (2.9) 2 (2.9)
Bilateral 3 (8.6) 0 (0.0) 3 (4.2)
Previous DVT, cause
Unprovoked 10 (28.6) 7 (20.0) 17 (24.3)
Provoked 25 (71.4) 28 (80.0) 53 (75.7)
Previous DVT, contributing risk factorsg 
Immobility 1 (4.0) 3 (10.7) 4 (7.5)
Surgical procedure 7 (28.0) 7 (25.0) 14 (26.4)
Trauma 5 (20.0) 5 (17.9) 10 (18.9)
Use of contraceptives 8 (32.0) 5 (17.9) 13 (24.5)
Pregnancy 6 (24.0) 8 (28.6) 14 (26.4)
(Continues)
 
Low INR 
range, n = 40
High INR 
range, n = 39 Total, n = 79
Thrombophilia, tested 12 (30.0) 14 (35.9) 26 (32.9)
Antiphospholipid 
syndrome
1 (8.3) 0 (0.0) 1 (3.8)
Factor V Leidenh  3 (25.0) 9 (64.3) 12 (46.2)
G20210A mutationh  0 (0.0) 1 (7.1) 1 (3.8)
No thrombophilia 8 (66.7) 5 (35.7) 13 (50.0)
Note: Results of the baseline characteristics are in n (%) or mean (± 
SD). Apart from the variables marked with ‘c’, none of the variables 
mentioned in this table showed statistical significant differences 
between groups.
CEAP, Clinical, Etiological, Anatomical, and Pathophysiological 
classification; DVT, deep vein thrombosis; LET, lower-extremity 
thrombosis; VCSS, Venous Clinical Severity Score.
aThe LET classification categorizes DVT of the lower extremity based 
on its most cranial localization in reference to the vein segments 
affected.22 LET I = calf vein thrombosis, LET II = femoropopliteal 
thrombosis, LET III = femoroiliac thrombosis, LET IV = inferior caval vein 
thrombosis. 
bThe VCSS represents the severity of venous pathology based on 10 
indicative features being pain, varicose veins, venous edema, skin 
pigmentation, inflammation, induration, active ulcers (including number, 
size, and duration) and the application of compression therapy. It is a 
dynamic score with a higher score (range, 0-30) meaning more severe 
complaints.26 The score differentiates between no (0-3), mild to 
moderate (4-7), or severe venous disease (≥8).27 
cP = .03. 
dThe CEAP-classification is a standardized score for chronic venous 
disorders describing its clinical (C), etiological (E), anatomical (A), and 
pathophysiological (P) characteristics.25 
eHighest clinical CEAP scores included either C3 (edema), C2 (varicose 
veins), C1 (telangiectasias or reticular veins), or C0 (no signs of disease). 
fPrevious DVT as reported by the patient during study assessment. 
gA patient can have multiple risk factors. 
hOne patient was both heterozygote for factor V Leiden as well as 
heterozygote for G20210A mutation. 
TA B L E  1   Continued
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TA B L E  2   Primary and secondary outcomes per patient group
 
Acute DVT 
N = 10
Chronic deep 
venous obstruction 
due to chronic 
postthrombotic 
sequelae, N = 64 P valuea 
Chronic 
deep venous 
obstruction due to 
(nonthrombotic) 
iliac vein 
compression 
syndromes, N = 5 Total, N = 79 P valueb 
In-stent thrombosis 4 (40.0) 12 (18.8) .27 0 (0.0) 16 (20.3) .15
Type of intervention
PTA with stenting 9 (90.0) 46 (71.9) .42 5 (100.0) 60 (75.9) .20
PTA with stenting and AVF 0 (0.0) 2 (3.1) .76 0 (0.0) 2 (2.5) .79
Endophlebectomy with PTA and 
stenting
0 (0.0) 3 (4.7) .95 0 (0.0) 3 (3.8) .69
Endophlebectomy with PTA, stenting, 
and AVF
1 (10.0) 13 (20.3) .79 0 (0.0) 14 (17.7) .41
Location stent
Left 5 (50.0) 30 (46.9) 1.00 1 (20.0) 36 (45.6) .49
Right 0 (0.0) 9 (14.1) 1.00 1 (20.0) 10 (12.7) .41
Caval 0 (0.0) 3 (4.7) .95 1 (20.0) 4 (5.1) .24
Bilateral (incl. cava) 4 (40.0) 10 (15.6) .17 0 (0.0) 14 (17.7) .10
Left incl. cava 0 (0.0) 10 (15.6) 1.00 1 (20.0) 11 (13.9) .38
Right incl. cava 1 (10.0) 2 (3.1) .72 0 (0.0) 3 (3.8) .51
Azygos vein 0 (0.0) 0 (0.0) .29 1 (20.0) 1 (1.3) .001
Type of anticoagulantc 
Acenocoumarol 9 (90.0) 33 (51.6) .04 3 (60.0) 45 (57.0) .07
Phenprocoumon 1 (10.0) 30 (46.9) .05 2 (40.0) 33 (41.8) .09
Unknown 0 (0.0) 1 (1.6) .54 0 (0.0) 1 (1.3) .89
Duration of anticoagulant therapy, d, 
median
182 (51-721) 344 (148-777) .29 497 (235-1278) 351 (136-769) .30
INR target range
2.0-3.5 6 (60.0) 30 (46.9) .67 4 (80.0) 40 (50.6) .30
2.5-4.0 4 (40.0) 34 (53.1) .67 1 (20.0) 39 (49.4) .30
INR, mean 3.08 (±0.63) 3.15 (±0.46) .69 3.12 (±0.38) 3.14 (± 0.47) .92
Time within therapeutic range, % (mean) 66.8 (±13.6) 63.2 (±19.5) .69 67.7 (±24.9) 64.01 (±19.01) .80
Proportion INR < 2.0, % (mean) 17.3 (±17.9) 10.7 (±10.5) .36 12.2 (±15.4) 11.62 (± 11.95) .35
LMWH indicated if INR < 2.5 beyond the initial treatment periodd 
Yes 5 (50.0) 22 (34.4) .54 1 (20.0) 28 (35.4) .48
No 5 (50.0) 42 (65.6) .54 4 (80.0) 51 (64.6) .48
Bleeding 0 (0.0) 2 (3.1) .76 0 (0.0) 2 (2.5) .79
Note: Results of the primary and secondary outcomes are in n (%), mean (± SD), or median (interquartile range) as appropriate.
AVF, arteriovenous fistula; DVT, deep vein thrombosis; INR, International Normalized Ratio; LMWH, low-molecular-weight heparin; PTA, 
percutaneous transluminal angioplasty.
aP value based on comparison between patients with an acute DVT (n = 10) versus patients with chronic deep venous obstruction due to 
postthrombotic sequelae (n = 64). 
bP value based on comparison between patients with an acute DVT (n = 10) versus patients with chronic deep venous obstruction due to postthrombotic 
sequelae (n = 64) versus patients with chronic deep venous obstruction due to (nonthrombotic) iliac vein compression syndromes (n = 5). 
cAntiplatelet agents were not part of standard care. A combined or subsequent treatment with carbasalatecalcium, rivaroxaban, or fraxiparin was 
seen in 3, 7, and 1 patient, respectively. 
dAnticoagulant therapy was preformed according to international guidelines5 in all patients. This included LMWH use if INR dropped below 2.0 
during the initial VKA (re)installment period. The initial treatment period was defined as the first 6 wks of (re)installment of VKA treatment following 
the performed stent placement. In some patients, supplementary low-molecular-weight heparin use was prescribed temporarily in case the INR 
dropped below 2.5 beyond the initial treatment period. 
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There was no recurrent venous thromboembolism (P = .97), and 
major bleeding (n = 2) occurred only in patients treated for chronic 
postthrombotic morbidity (P = .79). The major bleedings concerned a 
subdural hematoma and an intracapsular hepatic bleeding.
Using the ROC curves, a TTR cutoff point of 49.9% was found for 
an increased risk of developing in-stent thrombosis in the total study 
population. The Kaplan-Meier curve in Figure 1 shows a significantly 
lower cumulative incidence for in-stent thrombosis in patients with 
a TTR ≥ 49.9% compared to patients with a TTR < 49.9% (P = .01). 
Specified TTR cutoff points for patients treated in the acute phase 
or patients treated for chronic postthrombotic sequelae were 69.4% 
and 45.9%, respectively. Furthermore, overall an increased risk of 
in-stent thrombosis was seen when the INR was < 2.0 for more than 
9.9% of the time. In patients treated for an acute DVT, an increased 
risk of in-stent thrombosis was seen with an INR < 2.0 for more than 
21.7% of the time and in the case of chronic deep venous obstruc-
tion with postthrombotic sequelae, the cutoff point was determined 
at 9.9%. Lower TTR (TTR < 49.9%) was associated with a higher pro-
portion INR < 2.0 (P = .03).
The Cox regression analyses according to the various models 
in patients stented for chronic deep venous obstruction with post-
thrombotic sequelae (n = 64) are presented in Table 3. An increased 
risk of in-stent thrombosis associated with decreasing TTR was 
found in all models: the univariate model, the model adjusted for 
age and sex, the model adjusted for sex and VKA type, as well as the 
multivariable adjusted model. Per 1% TTR increase, this resulted in 
HR of 0.96 (0.92-0.99; P = .02) for all models. Per 10% TTR increase, 
all models showed an HR of 0.65 (0.46-0.94; P = .02). For the propor-
tion INR < 2.0 no significant impact on in-stent thrombosis develop-
ment could be demonstrated.
Figure 2A shows median TTRs between patients with and with-
out in-stent thrombosis: 58.9% (IQR, 38.4-73.7) versus 67.6% (IQR, 
56.4-76.3), respectively (P = .15). For patients that had experienced 
an in-stent thrombosis TTR is further subdivided according to treat-
ment indication and shown in Figure 2B: with a median TTR of 68.0% 
(IQR, 49.8-90.4) in patients treated during the acute phase versus 
43.9% (IQR, 35.6-71.6) in patients treated for chronic deep venous 
obstruction with postthrombotic sequelae (P = .27).
4  | DISCUSSION
In this study, we found that the quality of anticoagulant therapy was an 
important independent determinant for the development of in-stent 
thrombosis in patients after cavo-iliofemoral venous stent placement. 
F I G U R E  1   Kaplan-Meier: In-stent thrombosis comparing overall 
TTR*< or >49.9%. Kaplan-Meier curve presenting the development 
of in-stent thrombosis during VKA treatment comparing patients 
with an overall TTR< or >49.85%. The cutoff was based on 
the optimal combination of values (highest “sensitivity” and 
“1-specificity”) in the accompanying ROC curves.*TTR is calculated 
using the method as proposed by Rosendaal et al.28 ROC, receiver 
operating characteristic; TTR, time within therapeutic range; VKA, 
vitamin K antagonist
1,0 P = .01
TTR <49.9%
TTR>49.9%
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TA B L E  3   Hazard ratios for IST after stenting for chronic postthrombotic deep venous obstruction (n = 64)
 Univariable Age/Sex adjusteda  Sex/VKA type adjustedb  Multivariable adjustedc 
TTR (per 1% increase) 0.96 (0.92-0.99)d  0.96 (0.92-0.99)d  0.96 (0.92-0.99)d  0.96 (0.92-0.99)d 
TTR (per 10% increase) 0.65 (0.46-0.94)d  0.65 (0.46-0.94)d  0.65 (0.46-0.94)d  0.65 (0.46-0.94)d 
INR < 2.0 (per 1% increase) 1.01 (0.93-1.09) 0.99 (0.91-1.07) 0.99 (0.92-1.07) 0.98 (0.91-1.06)
INR < 2.0 (per 10% 
increase)
1.09 (0.48-2.46) 0.86 (0.37-2.00) 0.89 (0.41-1.95) 0.83 (0.37-1.86)
Note: Results are hazard ratio (95% CI) for IST development after venous stent placement indicated for chronic deep venous obstruction due to 
postthrombotic sequelae (n = 64).
INR, International Normalized Ratio; IST, in-stent thrombosis; TTR, time within therapeutic range.
aAdjusted for age and sex. 
bAdjusted for sex and VKA type (acenocoumarol or phenprocoumon). 
cAdjusted for age, sex, VKA type (acenocoumarol or phenprocoumon), and indication for LMWH use if INR < 2.5 following initial treatment period. 
dP = .02. 
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We identified TTR as the most important predictive variable reflect-
ing the quality of anticoagulant therapy and its associated risk for 
in-stent thrombosis. The impact of the quality of anticoagulant treat-
ment was found to be significant, showing that a 1% lower TTR was 
associated with a 4.2% increased risk of in-stent thrombosis, and each 
10% lower TTR was associated with a 34.6% increased risk of in-stent 
thrombosis.
We anticipated that for the onset of in-stent thrombosis, the pro-
portion of INR values < 2.0 would be even more important. However, 
we could not demonstrate a difference in proportion of INR < 2.0 
between groups. This may be due to the relatively small sample size 
and the lack of contrast in the population. The use of thrombopro-
phylaxis in case the INR would drop below < 2.5 in patients who 
developed in-stent thrombosis and those who did not may have re-
sulted in this lack of contrast and might explain why subtherapeutic 
INR could not be identified as a risk factor in this population.
The mean TTRs did not differ between patients with or with-
out in-stent thrombosis; there was, however, a significantly higher 
number of in-stent thromboses over time in patients with TTR 
<49.9%. An explanation for this could be that patients with low TTR 
experience more periods of INR fluctuation with variable efficacy 
of VKA; during periods of decreasing effects of anticoagulant, the 
relatively low concentrations of the natural anticoagulants protein 
C and protein S, compared to the quickly rising concentrations of 
active vitamin K–dependent procoagulant factors VII, IX, and X and 
prothrombin, might induce a temporary prothrombotic state irre-
spective of the INR value and may contribute to the risk of stent 
occlusion.
The target ranges used for anticoagulant treatment were at the 
discretion of the treating physician. Although patients with a “high” 
target INR presented with more severe venous disease, groups were 
highly comparable regarding baseline and interventional character-
istics. One might speculate that a worse clinical presentation may 
have prompted physicians to prescribe a higher target INR or that 
patients treated according to the “high” target INR had more serious 
postthrombotic morbidity based on a more pronounced thrombo-
genic risk profile. However, this could not be determined from our 
data. Either way, a “high” target INR did not provide better protection 
against in-stent thrombosis than the conventional “low” target INR.
At the time of this study, all patients received VKAs. No DOACs 
were prescribed, mainly because the uptake of DOACs in the Dutch 
medical practice has been relatively slow, and physicians might also 
have been hesitant to adopt DOACs and thereby change medication 
in patient groups presenting with more severe postthrombotic mor-
bidity. Treatment with DOACs provides more stable anticoagulation 
and has been associated with improved recanalization and reduced 
incidence of postthrombotic syndrome.31,32 It is therefore possible 
that DOACs might provide better protection against in-stent throm-
bosis, although this has not yet been objectified and requires further 
clinical study.33
An important limitation is the small sample size of our study. This 
can be explained by the fact that venous stenting was and still is a 
relatively new treatment modality that is not yet performed on a 
large scale. However, although over time venous stenting is being 
performed more frequently and experience with these procedures 
has increased, the risk of developing in-stent thrombosis following 
venous stent placement remains high.9 Another limitation associated 
with the small sample size is the fact that it is impossible to assess 
the contribution of specific characteristics of the stents used (eg, 
type, material, length, diameter), or the interventions performed (eg, 
stented vein segments, used technique, achieved patency) to the de-
velopment of in-stent thrombosis.
This study has several strengths including the prospective de-
sign, the clear definition of end points, objectively documented re-
currence, and regular follow-up of patients.
We conclude that the quality of anticoagulant treatment re-
flected in the TTR following a venous stenting procedure is an im-
portant determinant for the risk of in-stent thrombosis. Moreover, 
a “high” target INR does not result in a reduced risk of in-stent 
F I G U R E  2   A, TTR* in patients with and without in-stent 
thrombosis. Box-plot presenting the absolute TTR for patients 
with IST versus patients who did not develop IST. The box line 
represents the median, the box edges the 25th and 75th percentile, 
and the whiskers indicate the maximum values minus outliers. 
B, TTR* in patients with in-stent thrombosis, categorized per 
treatment indication. Box plot presenting the absolute TTR for 
patients with IST, categorized per treatment indication: acute 
DVT or chronic deep venous obstruction due to postthrombotic 
sequelae. The box line represents the median, the box edges the 
25th and 75th percentile, and the whiskers indicate the maximum 
values minus outliers. DVT, deep vein thrombosis; IST, in-stent 
thrombosis; TTR, time within therapeutic range. *TTR calculated as 
proposed by Rosendaal et al.28
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thrombosis compared to the regular “low” target INR but might in-
duce excess morbidity. The role of anticoagulant treatment including 
the use of DOACs for the prevention of in-stent thrombosis follow-
ing stenting procedures merits further research.
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